## CLAIMS

- 1. Stabilising formulation immunoglobulins polyclonal Ġ compositions, characterised that the formulation in includes sugar alcohol, glycine in a concentration between 7 10 g/l and a non-ionic detergent q/l and concentration between 20 and 50 ppm, in order to be suitable for the stabilisation of immunoglobulins G compositions in liquid form and in lyophilised form.
- 2. Stabilising formulation according to claim 1 consisting of the said sugar alcohol, glycine and non-ionic detergent.
  - 3. Formulation according to claim 1, characterized in that the sugar alcohol is mannitol.
- 15 4. Formulation according to claim 3, characterized in that the concentration of mannitol is between 30 g/l and 50 g/l.
- 5. Polyclonal immunoglobulins G composition in liquid form comprising, as stabiliser, 20 a stabilising formulation consisting of a sugar alcohol, glycine in a concentration between 7 g/l and 10 g/l and a non-ionic detergent in a concentration between 20 and 50 ppm.
- Polyclonal 6. immunoglobulins G 25 composition in lyophilised form, obtained by lyophilisation of a polyclonal immunoglobulins composition and a stabilising formulation including a sugar alcohol, glycine in a concentration between 7 q/l and 10 g/l and a non-ionic detergent 30 concentration between 20 and 50 ppm.
  - 7. Polyclonal immunoglobulins G composition according to claim 5, characterized in that it includes an amount of polymers less than 0.3% after a 6 months storage period at room temperature.

35

8. Polyclonal immunoglobulins G

composition according to claim 6, characterized in that it includes an amount of polymers less than 0.3 % after a 12 months storage period at room temperature or for 6 months at  $40\,^{\circ}\text{C}$ .

- 9. Polyclonal immunoglobulins G composition according to claim 5, characterized in that the composition includes an amount of dimers less than 7 % after a 24 months storage period at 4°C.
- 10. Use of a stabilising formulation according to claim 2 as stabiliser, for polyclonal immunoglobulins G compositions in liquid form obtained directly by fractioning of human plasma.
- 11. Use of a stabilising formulation 15 according to claim 1, for stabilisation of polyclonal immunoglobulins G compositions in lyophilised form.
- 12. Use of a stabilising formulation according to claim 1 for stabilisation of polyclonal immunoglobulins G compositions in liquid form 20 obtained after reconstitution in a suitable aqueous medium of polyclonal immunoglobulins G compositions in lyophilised form.